Nosopharm, a Lyon, France-based biotechnology company specialized in the research and development of new antimicrobial molecules, raised €2.4m in funding.
Backers included Auriga Partners, Kreaxi and Alto Invest, which joined Nosopharm’s long-standing shareholders.
The company intends to use the funds to accelerate the regulatory preclinical development of its first antibiotic molecule, NOSO-95179, which targets Enterobacteriaceae, a priority pathogen according to the WHO. First-in-man studies are expected to start in 2019.
Founded in 2009 and led by Philippe Villain-Guillot, president, Nosopharm is a biotechnology company specialized in the research and development of new antibacterial molecules. The company discovered and developed NOSO-95179, an antibiotic for the treatment of multidrug-resistant hospital-acquired infections. Nosopharm has developed an expertise in the discovery of natural bioactive products stemming from the Xenorhadbus and Photorhabdus microbial genus and in the medicinal chemistry of Odilorhabdin, the new class of antibiotics to which NOSO-95179 belongs.
The company, which has a staff of seven, has raised a total of €4.2M ($4.5M) in private equity and received €1.9M ($2M) in grants from IMI, DGA, Bpifrance, Region Languedoc-Roussillon and FEDER.